Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Single-Arm, Open-Label, Multicenter Study of the Safety of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

NCT07226206 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT07226206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07226206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Single-Arm, Open-Label, Multicenter Study of the Safety of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 8, 2026
Completion date
April 30, 2032
Enrollment
5 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a